Table 3 Baseline characteristics of the studied two groups of patients and posttreatment follow-up

AST (< 35 IU/ml)

39.04 ± 25.04

39.46 ± 22.72

27.30 ± 8.99

0.942

 < 0.001

ALT (< 35 IU/ml)

57.92 ± 71.10

62.14 ± 50.96

27.76 ± 10.99

0.769

 < 0.001

HCV RNA PCR

0.772 ± 0.1004

1.595 ± 1.89

Undetectable

0.016

-

I-FABP reference range (< 2 ng/ml)

6.91 ± 1.25

11.76 ± 7.26

20.11 ± 7.30

0.001

 < 0.001

I-FABP control range (6.09 ± 1.90 ng/ml)

6.91 ± 1.25 (p = 1.00)

11.76 ± 7.26 ( p  < 0.001)

20.11 ± 7.30

**

 < 0.001

Transient elastography (kPa)

4.42 ± 0.44

5.51 ± 1.26

5.48 ± 2.04

 < 0.001

0.928

Fibrosis stages

 < F2 n (%)

25 (100.0%)

41 (82.0%)

43 (86.0%)

0.025

0.727

 ≥ F2 n (%)

0

9 (18.0%)

7 (14.0%)

CAP (dB/m)

196.84 ± 39.06

212.92 ± 48.75

210.10 ± 48.44

0.156

0.634

Steatosis grades

 < S2 n (%)

23 (92.0%)

44 (88.0%)

44 (88.0%)

0.711

1

 ≥ S2 n (%)

2 (8.0%)

6 (12.0%)

6 (12.0%)

FIB4

1.21 ± 0.57

0.96 ± 0.62

0.82 ± 0.45

0.107

0.019

APRI score

0.50 ± 0.45

0.40 ± 0.30

0.25 ± 0.11

0.252

 < 0.001